Comparing Cabaletta Bio (NASDAQ:CABA) and ZyVersa Therapeutics (NASDAQ:ZVSA)

ZyVersa Therapeutics (NASDAQ:ZVSA) and Cabaletta Bio (NASDAQ:CABA) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their profitability, risk, institutional ownership, dividends, analyst recommendations, valuation and earnings.

Institutional and Insider Ownership

3.9% of ZyVersa Therapeutics shares are held by institutional investors. 0.2% of ZyVersa Therapeutics shares are held by company insiders. Comparatively, 6.4% of Cabaletta Bio shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Risk and Volatility

ZyVersa Therapeutics has a beta of 0.83, meaning that its share price is 17% less volatile than the S&P 500. Comparatively, Cabaletta Bio has a beta of 3.26, meaning that its share price is 226% more volatile than the S&P 500.

Profitability

This table compares ZyVersa Therapeutics and Cabaletta Bio’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
ZyVersa Therapeutics	N/A	-109.54%	-43.95%
Cabaletta Bio	N/A	-131.58%	-96.46%

Valuation and Earnings

This table compares ZyVersa Therapeutics and Cabaletta Bio”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ZyVersa Therapeutics	N/A	N/A	-$9.41 million	($0.83)	-0.14
Cabaletta Bio	N/A	N/A	-$167.86 million	($1.96)	-1.40

Cabaletta Bio is trading at a lower price-to-earnings ratio than ZyVersa Therapeutics, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a breakdown of current recommendations and price targets for ZyVersa Therapeutics and Cabaletta Bio, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ZyVersa Therapeutics	0	0	0	0	0.00
Cabaletta Bio	1	1	5	0	2.57

Cabaletta Bio has a consensus target price of $15.50, indicating a potential upside of 463.64%. Given Cabaletta Bio’s stronger consensus rating and higher probable upside, analysts plainly believe Cabaletta Bio is more favorable than ZyVersa Therapeutics.

Summary

ZyVersa Therapeutics beats Cabaletta Bio on 6 of the 11 factors compared between the two stocks.

About ZyVersa Therapeutics

ZyVersa Therapeutics, Inc., a clinical stage biopharmaceutical company, develops and commercializes products for the treatment of renal and inflammatory diseases. The company develops drug development platforms, including Cholesterol Efflux Mediator VAR 200, an injectable drug, which is in Phase 2a clinical trial to the treatment of renal indications, such as focal segmental glomerulosclerosis, alport syndrome, and diabetic kidney diseases; and Inflammasome ASC Inhibitor IC 100, a humanized monoclonal antibody that is in preclinical stage for treatment of inflammatory diseases comprising acute respiratory syndrome, multiple sclerosis, IgA neuropathy, pancreatic cancer, Parkinson's and Huntington's disease, atherosclerosis, Alzheimer's disease, and obesity. ZyVersa Therapeutics, Inc. was founded in 2014 and is headquartered in Weston, Florida.

About Cabaletta Bio

Cabaletta Bio, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of engineered T cell therapies for patients with B cell-mediated autoimmune diseases. The company's lead product candidate is CABA-201, a fully human anti-CD19 binder for the treatment of Phase 1/2 clinical trials in dermatomyositis, anti-synthetase syndrome, immune-mediated necrotizing myopathy, lupus nephritis, non-renal systemic lupus erythematosus, systemic sclerosis, and generalized myasthenia gravis. It also develops DSG3-CAART, which is in Phase I/II clinical trial for the treatment of mucosal pemphigus vulgaris; and MuSK-CAART, an investigational cell therapy that is in Phase I/II clinical trial for treating patients with anti- muscle-specific kinase antibody positive myasthenia gravis. It has a collaboration with the University of Pennsylvania and the Children's Hospital of Philadelphia; Nanjing IASO Biotherapeutics Co., Ltd; Oxford Biomedica; and WuXi Advanced Therapies, Inc. The company was formerly known as Tycho Therapeutics, Inc. and changed its name to Cabaletta Bio, Inc. in August 2018. Cabaletta Bio, Inc. was incorporated in 2017 and is headquartered in Philadelphia, Pennsylvania.